Opening neck arteries didn't protect thinking
Changes what you do: 1 yes · 2 not yet · 0 no
◆◆◆◇◇ Every study sits on a five-step ladder, from lab to a person's actual outcome. How to read it
Take◆◆◆◆◇ People, tested on a stand-in
Opening severely narrowed neck arteries did not protect thinking at one year
| Who | Adults with severely narrowed carotid (neck) arteries |
|---|---|
| How many | Not reported |
| How long | 1 year |
| Design | Randomised trial (People, tested on a stand-in): stent or surgery plus medication versus medication alone |
| Measured | Cognitive outcomes at one year, OUTCOMESTAND-IN |
A badly narrowed artery in the neck can be opened with a stent or surgery. One reason patients hear for doing it is that restoring blood flow protects the brain. That reason has now been tested head-on.
Patients with severe narrowing were assigned at random to a procedure plus medication, or to medication alone. A year later, the procedure arms showed no cognitive advantage over medication alone. The sample size is unreported, so how large a benefit the trial could have detected is unknown. Random assignment is what makes this convincing, because the fitter patients cannot all have ended up in one group.
The trial measured thinking, not strokes, so it is not a verdict on stroke prevention. One year is also a short window for a brain. 1
HARMSNot measured. Complication rates from the stent and surgery arms are unreported, so an absent benefit is on the record without the matching risks.
WHAT WOULD MOVE THISA five-year follow-up of the same patients showing a cognitive difference, or a trial in people whose thinking problems are already tied to reduced blood flow.
1 SciTechDaily · randomized controlled trial comparing carotid stenting/surgery plus medication vs. medication alone on cognitive outcomes
Take Not a study
A geriatrics guidance article names muscle loss and frailty as risks of GLP-1 drugs in older adults
| Who | Older adults prescribed GLP-1 and related agonists; separately, UK Biobank adults |
|---|---|
| How many | 438,748 in the cohort; no sample given for the guidance |
| How long | Median 13.8 years |
| Design | Prescribing guidance with no design stated, so no stage applies, plus a prospective population cohort (People, watched): watched, not tested |
| Measured | Death, cirrhosis, liver cancer, heart and kidney disease, cancer, OUTCOME |
If you or a parent takes a GLP-1 weight-loss drug, the scale is not the only number that matters. A geriatrics guidance article applying the 5Ms framework names two risks of this class: frailty, and sarcopenia, the loss of muscle mass and strength.
That guidance is clinical judgement with no study behind it. Separately, in 438,748 UK adults followed a median of 13.8 years, low-muscle markers alongside fatty liver disease tracked with higher death rates across every obesity state. That cohort tested no drug: it establishes that low muscle alongside fatty liver is prognostically bad, not that GLP-1 drugs cause either. India's food regulator has already challenged a muscle-preservation claim sold alongside GLP-1 therapy.
The UK Biobank participants were watched, not tested, and that cohort was not a study of GLP-1 drugs. Whether any participant was taking one is not in the available reporting. So this is a reason to ask about muscle, not evidence that the drugs cause harm. 2–4
HARMSReported as named risks rather than measured rates: the guidance names sarcopenia and frailty in older adults on this drug class, with no frequencies attached.
WHAT WOULD MOVE THISA randomised trial in older adults on a GLP-1 drug measuring what people can physically do, not only what they weigh.
2 Journal of the American Geriatrics Society · Not a study · 3 prospective population cohort study (UK Biobank) · n = 438,748 · 4 ET HealthWorld · Not a study
Measure◆◆◆◇◇ People, watched
Missing teeth tracked with worse daily function in England, the United States and India
| Who | Adults aged 60 and over in three national aging studies |
|---|---|
| How many | 63,074 in all |
| How long | Not reported |
| Design | Harmonised cross-national cohort analysis (People, watched): watched, not tested |
| Measured | Ability to manage daily and household activities, OUTCOME |
Losing teeth gets treated as a dental problem, sometimes a cosmetic one. In adults over 60, it travelled with something larger: difficulty with the everyday tasks that keep a person independent, from washing and dressing to shopping and handling money.
Three national aging studies were harmonised, 63,074 adults in all. The same association turned up in each of the three. Nobody's teeth were restored to see whether function followed.
India's LASI supplied the largest of the three samples, 31,816 of the 63,074 adults, so this is not a Western finding offered an India angle afterwards. Restoring dentition is cheap in India and is not usually counted as aging care. Whether a repaired bite gives function back is the untested step. 5
HARMSNot measured. No dental treatment was given or tested here, so neither benefit nor harm from dentures, extraction or implants is on the record.
WHAT WOULD MOVE THISA trial that restores dentition in older adults and measures whether they manage daily tasks better a year later.
5 harmonized cross-national longitudinal cohort analysis (ELSA, HRS, LASI) with cross-sectional IPW methods · n = 63,074
This week's strongest human evidence. A prespecified analysis of pooled randomised trial data in 466,320 older adults found high-dose flu vaccine beat standard-dose at preventing hospitalisation (People, tested on what matters). Separately, a 10-year randomised trial in chronic kidney disease found a fruit-and-vegetable diet produced fewer hospital visits than standard alkali treatment, at no higher cost (People, tested on what matters). Neither changes what to do today -- the vaccine finding is about which dose, not whether to get one, and the diet trial has no at-home protocol to follow from the available reporting. 6,7
Mouse lifespan claims. A senolytic vaccine given late in life raised median lifespan 12% in female mice, and exercise-triggered bone proteins were tied to longer life. Single groups, median lifespan only, no replication. 8,9
Peptide injections. A temporary US policy lets compounding pharmacies distribute certain unapproved peptide injections, while regulators warned consumers off two products for undisclosed ingredients. Easier to buy, and the policy creates no mechanism to collect safety or efficacy data on what gets sold. 10–12
Prenuvo. Prenuvo published findings from its own customer base. In 14,031 people who paid for their own whole-body MRI, better sleep efficiency tracked with less visceral fat, and sleeping past eight hours with a smaller hippocampus. A one-off snapshot of self-selected customers. 13
Aging clocks. Forty-eight methylation clocks were pooled against death risk across 380,705 people, and a new proteomic clock appeared. Neither was tested as a tool for deciding anything. 14,15
